Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers

ConclusionSix cycles of TEC with prophylactic G-CSF is an effective and tolerable neoadjuvant regime for HER2-negative breast cancers. Hematological toxicities were the most common toxicities. Although many patients required dose reduction, all patients completed treatment and there was no observed cardiotoxicity.

http://link.springer.com/10.1007/s12325-021-01933-1

Source: Advances in Therapy - October 26, 2021 Category: Drugs & Pharmacology Source Type: research